Cargando…
Sustained Lesion and Shedding Rate Reductions in Genital Herpes Patients 24 Months after Immunization with GEN-003, a Genital Herpes Immunotherapy
BACKGROUND: Herpes simplex viruses (HSVs) are the main cause of genital ulcers worldwide. GEN-003 is an investigational genital herpes immunotherapy composed of HSV-2 antigens gD2DTMR and ICP4.2, and the saponin-based adjuvant Matrix-M2(TM) (MM2). In a Phase 2 dose-ranging study (GEN-003-002), 3 dos...
Autores principales: | Heineman, Thomas, Mcneil, Lisa K, Oliphant, Thomas, Natenshon, Andrew, Van Wagoner, Nicholas, Flechtner, Jessica B, Hetherington, Seth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632159/ http://dx.doi.org/10.1093/ofid/ofx163.720 |
Ejemplares similares
-
Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Vs Placebo
por: Heineman, Thomas C, et al.
Publicado: (2017) -
1333 Therapeutic HSV-2 vaccine (GEN003) results in durable reduction in genital lesions at 1 year
por: Wald, Anna, et al.
Publicado: (2014) -
Herpes genital .
por: Rivera Gómez, Jesús
Publicado: (1996) -
Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial
por: Bernstein, David I., et al.
Publicado: (2017) -
Herpes genital : revisión bibliográfica
por: Macedo Díaz, Adriana
Publicado: (1999)